Lymphocytic vasculitis in X-linked lymphoproliferative disease.

Systemic vasculitis is an uncommon manifestation of X-linked lymphoproliferative disease (XLP), a disorder in which there is a selective immune deficiency to Epstein-Barr virus (EBV). The molecular basis for XLP has recently been ascribed to mutations within SLAM-associated protein (SAP), an SH2 domain-containing protein expressed primarily in T cells. The authors describe a patient who died as a result of chronic systemic vasculitis and fulfilled clinical criteria for the diagnosis of XLP. Sequencing of this patient's SAP gene uncovered a novel point mutation affecting the SH2 domain. The patient presented with virus-associated hemophagocytic syndrome (VAHS) and later had chorioretinitis, bronchiectasis, and hypogammaglobulinemia develop. He further developed mononeuritis and fatal respiratory failure. Evidence of widespread small and medium vessel vasculitis was noted at autopsy with involvement of retinal, cerebral, and coronary arteries as well as the segmental vessels of the kidneys, testes, and pancreas. Immunohistochemical analysis using antibodies to CD20, CD45RO, and CD8 revealed that the vessel wall infiltrates consisted primarily of CD8(+) T cells, implying a cytotoxic T-lymphocyte response to antigen. EBV DNA was detected by polymerase chain reaction (PCR) in arterial wall tissue microdissected from infiltrated vessels further suggesting that the CD8(+) T cells were targeting EBV antigens within the endothelium. The authors propose that functional inactivation of the SAP protein can impair the immunologic response to EBV, resulting in systemic vasculitis.

[1]  M. Bennett,et al.  Cloning and characterization of the 2B4 gene encoding a molecule associated with non-MHC-restricted killing mediated by activated natural killer cells and T cells. , 1993, Journal of immunology.

[2]  S R Goldstein,et al.  Laser capture microdissection of single cells from complex tissues. , 1999, BioTechniques.

[3]  D. Purtilo,et al.  Deficient natural killer cell activity in x-linked lymphoproliferative syndrome. , 1980, Science.

[4]  D. Baltimore,et al.  Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo , 1992, Molecular and cellular biology.

[5]  M. Dillon,et al.  Childhood vasculitis , 1998, Lupus.

[6]  P. Lai,et al.  Defective control of Epstein‐Barr virus‐infected B cell growth in patients with X‐linked lymphoproliferative disease , 1991, Clinical and experimental immunology.

[7]  R. Petty,et al.  A syndrome of childhood polyarteritis. , 1977, The Journal of pediatrics.

[8]  D. Hayoz,et al.  SH2D1A mutation analysis for diagnosis of XLP in typical and atypical patients , 1999, Human Genetics.

[9]  H. Pabst,et al.  Cutting Edge: Defective NK Cell Activation in X-Linked Lymphoproliferative Disease1 , 2000, The Journal of Immunology.

[10]  I. Ernberg,et al.  Cellular immune defects to Epstein-Barr virus-determined antigens in young males. , 1981, Cancer research.

[11]  Y. Ench,et al.  Characterization of natural Epstein‐Barr virus infection and replication in smooth muscle cells from a leiomyosarcoma , 1999, Journal of medical virology.

[12]  S. Tangye,et al.  Cutting edge: human 2B4, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP. , 1999, Journal of immunology.

[13]  E. Snyder,et al.  Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Jack R. Davis,et al.  X-Linked Lymphoproliferative Disease: Twenty-Five Years after the Discovery , 1995, Pediatric Research.

[15]  D. Purtilo,et al.  Cell‐mediated immunity to Epstein‐Barr virus (EBV) and natural killer (NK)‐cell activity in the X‐linked lymphoproliferative syndrome , 1982, International journal of cancer.

[16]  H. Ochs,et al.  Necrotizing lymphoid vasculitis in X-linked lymphoproliferative syndrome. , 1985, Archives of pathology & laboratory medicine.

[17]  A. Rickinson Epstein-Barr virus. , 2001, Virus research.

[18]  U. Nater,et al.  Epstein-Barr virus. , 1991, The Journal of family practice.

[19]  G. Vawter,et al.  X-LINKED RECESSIVE PROGRESSIVE COMBINED VARIABLE IMMUNODEFICIENCY (DUNCAN'S DISEASE) , 1975, The Lancet.

[20]  C Terhorst,et al.  Crystal structures of the XLP protein SAP reveal a class of SH2 domains with extended, phosphotyrosine-independent sequence recognition. , 1999, Molecular cell.

[21]  D. Moss,et al.  Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. , 1997, Annual review of immunology.

[22]  K. Hayashi,et al.  Chronic active Epstein-Barr virus infection with giant coronary aneurysms. , 1996, American journal of clinical pathology.

[23]  L. Guillevin,et al.  Polyarteritis nodosa, microscopic polyangiitis and Churg–Strauss syndrome , 1998, Lupus.

[24]  Jack R. Davis,et al.  Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene , 1998, Nature Genetics.

[25]  D. Allen,et al.  The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM , 1998, Nature.

[26]  S. Argov,et al.  Defective natural killing activity but retention of lymphocyte-mediated antibody-dependent cellular cytotoxicity in patients with the X-linked lymphoproliferative syndrome. , 1986, Cellular immunology.

[27]  Jack R. Davis,et al.  The X-linked lymphoproliferative disease: from autopsy toward cloning the gene 1975-1990. , 1991, Pediatric pathology.

[28]  B. Cocks,et al.  Engagement of the signaling lymphocytic activation molecule (SLAM) on activated T cells results in IL-2-independent, cyclosporin A-sensitive T cell proliferation and IFN-gamma production. , 1997, Journal of immunology.

[29]  H. Grossniklaus,et al.  Retinal necrosis in X-linked lymphoproliferative disease. , 1994, Ophthalmology.

[30]  B. Griffin,et al.  Clustered repeat sequences in the genome of Epstein Barr virus. , 1983, Nucleic acids research.

[31]  J. Saffitz,et al.  Murine gamma-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-gamma responsiveness: a new model for virus-induced vascular disease. , 1997, Nature medicine.

[32]  K. Aozasa,et al.  Large-vessel arteritis associated with chronic active Epstein-Barr virus infection. , 1998, Arthritis and rheumatism.

[33]  H. Takeuchi,et al.  Systemic granulomatous arteritis associated with Epstein-Barr virus infection , 1999, Virchows Archiv.

[34]  W. Crist,et al.  Fatal Epstein-Barr virus-associated hemophagocytic syndrome. , 1981, The Journal of pediatrics.

[35]  A. Purohit,et al.  A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells. , 1993, Journal of immunology.